Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.30
CBPO's Cash to Debt is ranked lower than
76% of the 841 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. CBPO: 1.30 )
Ranked among companies with meaningful Cash to Debt only.
CBPO' s 10-Year Cash to Debt Range
Min: 0.65  Med: 6.43 Max: 306.77
Current: 1.3
0.65
306.77
Equity to Asset 0.54
CBPO's Equity to Asset is ranked lower than
66% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. CBPO: 0.54 )
Ranked among companies with meaningful Equity to Asset only.
CBPO' s 10-Year Equity to Asset Range
Min: 0.29  Med: 0.54 Max: 0.67
Current: 0.54
0.29
0.67
Interest Coverage 30.06
CBPO's Interest Coverage is ranked lower than
86% of the 375 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CBPO: 30.06 )
Ranked among companies with meaningful Interest Coverage only.
CBPO' s 10-Year Interest Coverage Range
Min: 6.9  Med: 35.62 Max: 93.8
Current: 30.06
6.9
93.8
F-Score: 6
Z-Score: 11.53
M-Score: -2.73
WACC vs ROIC
13.39%
42.70%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 45.83
CBPO's Operating margin (%) is ranked higher than
95% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. CBPO: 45.83 )
Ranked among companies with meaningful Operating margin (%) only.
CBPO' s 10-Year Operating margin (%) Range
Min: 21.04  Med: 43.13 Max: 51.58
Current: 45.83
21.04
51.58
Net-margin (%) 29.46
CBPO's Net-margin (%) is ranked higher than
91% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. CBPO: 29.46 )
Ranked among companies with meaningful Net-margin (%) only.
CBPO' s 10-Year Net-margin (%) Range
Min: 1.86  Med: 24.86 Max: 29.15
Current: 29.46
1.86
29.15
ROE (%) 36.36
CBPO's ROE (%) is ranked higher than
96% of the 761 Companies
in the Global Biotechnology industry.

( Industry Median: -29.50 vs. CBPO: 36.36 )
Ranked among companies with meaningful ROE (%) only.
CBPO' s 10-Year ROE (%) Range
Min: 5.04  Med: 27.33 Max: 42.37
Current: 36.36
5.04
42.37
ROA (%) 17.35
CBPO's ROA (%) is ranked higher than
94% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: -25.57 vs. CBPO: 17.35 )
Ranked among companies with meaningful ROA (%) only.
CBPO' s 10-Year ROA (%) Range
Min: 1.84  Med: 16.03 Max: 23.86
Current: 17.35
1.84
23.86
ROC (Joel Greenblatt) (%) 62.45
CBPO's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -333.14 vs. CBPO: 62.45 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
CBPO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 72.32  Med: 89.14 Max: 211.2
Current: 62.45
72.32
211.2
Revenue Growth (3Y)(%) 18.20
CBPO's Revenue Growth (3Y)(%) is ranked higher than
76% of the 404 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. CBPO: 18.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
CBPO' s 10-Year Revenue Growth (3Y)(%) Range
Min: 8.3  Med: 18.20 Max: 57.5
Current: 18.2
8.3
57.5
EBITDA Growth (3Y)(%) 36.60
CBPO's EBITDA Growth (3Y)(%) is ranked higher than
87% of the 427 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. CBPO: 36.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
CBPO' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 5.5  Med: 27.00 Max: 72.3
Current: 36.6
5.5
72.3
EPS Growth (3Y)(%) 59.50
CBPO's EPS Growth (3Y)(%) is ranked higher than
95% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. CBPO: 59.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
CBPO' s 10-Year EPS Growth (3Y)(%) Range
Min: 6.7  Med: 52.00 Max: 156.1
Current: 59.5
6.7
156.1
» CBPO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

CBPO Guru Trades in Q2 2014

Jim Simons 200,100 sh (+53.48%)
Steven Cohen 8,000 sh (unchged)
Chuck Royce 2,900 sh (unchged)
» More
Q3 2014

CBPO Guru Trades in Q3 2014

Jim Simons 222,600 sh (+11.24%)
Chuck Royce 2,900 sh (unchged)
Steven Cohen Sold Out
» More
Q4 2014

CBPO Guru Trades in Q4 2014

Pioneer Investments 5,525 sh (New)
Jim Simons 276,100 sh (+24.03%)
Chuck Royce 2,900 sh (unchged)
» More
Q1 2015

CBPO Guru Trades in Q1 2015

Jim Simons 348,722 sh (+26.30%)
Chuck Royce Sold Out
Pioneer Investments Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with CBPO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 42.18
CBPO's P/E(ttm) is ranked higher than
51% of the 215 Companies
in the Global Biotechnology industry.

( Industry Median: 41.60 vs. CBPO: 42.18 )
Ranked among companies with meaningful P/E(ttm) only.
CBPO' s 10-Year P/E(ttm) Range
Min: 2.92  Med: 16.02 Max: 124.23
Current: 42.18
2.92
124.23
Forward P/E 23.42
CBPO's Forward P/E is ranked higher than
52% of the 162 Companies
in the Global Biotechnology industry.

( Industry Median: 24.04 vs. CBPO: 23.42 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 39.80
CBPO's PE(NRI) is ranked lower than
51% of the 213 Companies
in the Global Biotechnology industry.

( Industry Median: 39.20 vs. CBPO: 39.80 )
Ranked among companies with meaningful PE(NRI) only.
CBPO' s 10-Year PE(NRI) Range
Min: 2.92  Med: 14.55 Max: 129.2
Current: 39.8
2.92
129.2
P/B 12.90
CBPO's P/B is ranked lower than
82% of the 747 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. CBPO: 12.90 )
Ranked among companies with meaningful P/B only.
CBPO' s 10-Year P/B Range
Min: 0.84  Med: 2.91 Max: 12.9
Current: 12.9
0.84
12.9
P/S 12.20
CBPO's P/S is ranked higher than
50% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.60 vs. CBPO: 12.20 )
Ranked among companies with meaningful P/S only.
CBPO' s 10-Year P/S Range
Min: 0.68  Med: 2.12 Max: 12.21
Current: 12.2
0.68
12.21
PFCF 41.56
CBPO's PFCF is ranked higher than
53% of the 144 Companies
in the Global Biotechnology industry.

( Industry Median: 45.01 vs. CBPO: 41.56 )
Ranked among companies with meaningful PFCF only.
CBPO' s 10-Year PFCF Range
Min: 1.22  Med: 9.44 Max: 41.56
Current: 41.56
1.22
41.56
POCF 32.03
CBPO's POCF is ranked higher than
58% of the 203 Companies
in the Global Biotechnology industry.

( Industry Median: 35.83 vs. CBPO: 32.03 )
Ranked among companies with meaningful POCF only.
CBPO' s 10-Year POCF Range
Min: 1.01  Med: 6.84 Max: 32.03
Current: 32.03
1.01
32.03
EV-to-EBIT 23.43
CBPO's EV-to-EBIT is ranked higher than
66% of the 224 Companies
in the Global Biotechnology industry.

( Industry Median: 32.56 vs. CBPO: 23.43 )
Ranked among companies with meaningful EV-to-EBIT only.
CBPO' s 10-Year EV-to-EBIT Range
Min: 1.2  Med: 5.40 Max: 26.6
Current: 23.43
1.2
26.6
PEG 2.01
CBPO's PEG is ranked higher than
67% of the 73 Companies
in the Global Biotechnology industry.

( Industry Median: 2.63 vs. CBPO: 2.01 )
Ranked among companies with meaningful PEG only.
CBPO' s 10-Year PEG Range
Min: 0.43  Med: 1.13 Max: 2.15
Current: 2.01
0.43
2.15
Shiller P/E 87.55
CBPO's Shiller P/E is ranked lower than
70% of the 109 Companies
in the Global Biotechnology industry.

( Industry Median: 49.43 vs. CBPO: 87.55 )
Ranked among companies with meaningful Shiller P/E only.
CBPO' s 10-Year Shiller P/E Range
Min: 27.89  Med: 41.91 Max: 87.55
Current: 87.55
27.89
87.55
Current Ratio 2.51
CBPO's Current Ratio is ranked lower than
69% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.37 vs. CBPO: 2.51 )
Ranked among companies with meaningful Current Ratio only.
CBPO' s 10-Year Current Ratio Range
Min: 1.03  Med: 2.42 Max: 5.78
Current: 2.51
1.03
5.78
Quick Ratio 1.67
CBPO's Quick Ratio is ranked lower than
74% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. CBPO: 1.67 )
Ranked among companies with meaningful Quick Ratio only.
CBPO' s 10-Year Quick Ratio Range
Min: 0.54  Med: 1.48 Max: 3.92
Current: 1.67
0.54
3.92
Days Inventory 409.39
CBPO's Days Inventory is ranked lower than
92% of the 399 Companies
in the Global Biotechnology industry.

( Industry Median: 118.21 vs. CBPO: 409.39 )
Ranked among companies with meaningful Days Inventory only.
CBPO' s 10-Year Days Inventory Range
Min: 280.18  Med: 433.17 Max: 490.33
Current: 409.39
280.18
490.33
Days Sales Outstanding 40.48
CBPO's Days Sales Outstanding is ranked higher than
70% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. CBPO: 40.48 )
Ranked among companies with meaningful Days Sales Outstanding only.
CBPO' s 10-Year Days Sales Outstanding Range
Min: 2.44  Med: 24.03 Max: 39.95
Current: 40.48
2.44
39.95

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 28.86
CBPO's Price/Net Current Asset Value is ranked lower than
85% of the 538 Companies
in the Global Biotechnology industry.

( Industry Median: 7.59 vs. CBPO: 28.86 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
CBPO' s 10-Year Price/Net Current Asset Value Range
Min: 2.4  Med: 7.95 Max: 695
Current: 28.86
2.4
695
Price/Tangible Book 13.49
CBPO's Price/Tangible Book is ranked lower than
77% of the 687 Companies
in the Global Biotechnology industry.

( Industry Median: 5.90 vs. CBPO: 13.49 )
Ranked among companies with meaningful Price/Tangible Book only.
CBPO' s 10-Year Price/Tangible Book Range
Min: 1.16  Med: 3.62 Max: 24.65
Current: 13.49
1.16
24.65
Price/Projected FCF 4.35
CBPO's Price/Projected FCF is ranked higher than
54% of the 157 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. CBPO: 4.35 )
Ranked among companies with meaningful Price/Projected FCF only.
CBPO' s 10-Year Price/Projected FCF Range
Min: 0.85  Med: 1.43 Max: 3.4
Current: 4.35
0.85
3.4
Price/Median PS Value 5.76
CBPO's Price/Median PS Value is ranked lower than
93% of the 540 Companies
in the Global Biotechnology industry.

( Industry Median: 1.19 vs. CBPO: 5.76 )
Ranked among companies with meaningful Price/Median PS Value only.
CBPO' s 10-Year Price/Median PS Value Range
Min: 0.42  Med: 0.99 Max: 4.5
Current: 5.76
0.42
4.5
Price/Peter Lynch Fair Value 2.22
CBPO's Price/Peter Lynch Fair Value is ranked higher than
53% of the 49 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. CBPO: 2.22 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
CBPO' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.53  Med: 1.03 Max: 1.73
Current: 2.22
0.53
1.73
Price/Graham Number 4.23
CBPO's Price/Graham Number is ranked lower than
56% of the 171 Companies
in the Global Biotechnology industry.

( Industry Median: 3.52 vs. CBPO: 4.23 )
Ranked among companies with meaningful Price/Graham Number only.
CBPO' s 10-Year Price/Graham Number Range
Min: 0.36  Med: 1.18 Max: 4.44
Current: 4.23
0.36
4.44
Earnings Yield (Greenblatt) (%) 4.30
CBPO's Earnings Yield (Greenblatt) (%) is ranked higher than
91% of the 813 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. CBPO: 4.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
CBPO' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 3.8  Med: 18.60 Max: 84.3
Current: 4.3
3.8
84.3
Forward Rate of Return (Yacktman) (%) 20.29
CBPO's Forward Rate of Return (Yacktman) (%) is ranked higher than
64% of the 88 Companies
in the Global Biotechnology industry.

( Industry Median: 14.22 vs. CBPO: 20.29 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
CBPO' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 19.1  Med: 20.50 Max: 35.3
Current: 20.29
19.1
35.3

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:0CB.Germany,
China Biologic Products Inc was originally incorporated on December 20, 1989 under the laws of the State of Texas as Shepherd Food Equipment, Inc. On November 20, 2000, Shepherd Food Equipment, Inc. changed its corporate name to Shepherd Food Equipment, Inc. Acquisition Corp., which is the survivor of a merger with GRC Holdings, Inc. on May 28, 2003. On January 10, 2007, the Company was converted into a Delaware corporation and changed its name to China Biologic Products, Inc. It is a biopharmaceutical company which is engaged in the research, development, manufacturing and sales of human plasma-based pharmaceutical products in China. The Company has two majority subsidiaries, Shandong Taibang, a company based in Tai'an, Shandong Province and Guizhou Taibang, a company based in Guiyang, Guizhou Province. The Company's products are human albumin and immunoglobulin products. Albumin has been used for almost 50 years to treat critically ill patients by replacing lost fluid and maintaining adequate blood volume and pressure. Immunoglobulin is used for certain disease prevention and treatment by enhancing specific immunity. These products use human plasma as the principal raw material. Human albumin and human immunoglobulin for intravenous injection, or IVIG products, are the top-selling products. The Company sells its products to hospitals and inoculation centers in the PRC directly or through approved distributors.
» More Articles for CBPO

Headlines

Articles On GuruFocus.com
Weekly CFO Sells Highlight: ULTA, MIND, DG, PSA, CBPO, CNK Dec 20 2011 
Weekly CEO Sells Highlight: CTSH, CBPO, TCB, SRCL Sep 12 2010 
China Biologic Products Amends Agreement to Acquire 90% Controlling Interest in Chongqing Dalin Biol Dec 18 2008 

More From Other Websites
China Biologic Products to Report Second Quarter 2015 Financial Results Jul 24 2015
China Biologic Products to Report Second Quarter 2015 Financial Results Jul 24 2015
China Biologic Products (CBPO) in Focus: Stock Up 5.7% - Tale of the Tape Jul 10 2015
Coverage initiated on China Biologic Products by BofA/Merrill Jul 09 2015
Atara Biotherapeutics (ATRA) Crumbles: Stock Plunges 14.6% - Tale of the Tape Jul 02 2015
CHINA BIOLOGIC PRODUCTS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security... Jun 23 2015
CHINA BIOLOGIC PRODUCTS, INC. Files SEC form 8-K, Regulation FD Disclosure Jun 16 2015
A Chinese Biotechnology Company Gets On The Radar -- And Doubles Jun 15 2015
CHINA BIOLOGIC PRODUCTS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other... Jun 10 2015
China Biologic Announces Pricing of Public Offering of Common Stock Jun 10 2015
China Biologic Announces Pricing of Public Offering of Common Stock Jun 10 2015
Can The Uptrend Continue for China Biologic Products (CBPO)? - Tale of the Tape Jun 05 2015
CHINA BIOLOGIC PRODUCTS, INC. Financials May 15 2015
China Biologic Reports Financial Results for the First Quarter of 2015 May 06 2015
CHINA BIOLOGIC PRODUCTS, INC. Files SEC form 8-K, Results of Operations and Financial Condition May 06 2015
China Biologic Reports Financial Results for the First Quarter of 2015 May 06 2015
CHINA BIOLOGIC PRODUCTS, INC. Files SEC form 10-Q, Quarterly Report May 06 2015
Q1 2015 China Biologic Products Inc Earnings Release - After Market Close May 06 2015
China Biologic Products to Report First Quarter 2015 Financial Results Apr 28 2015
China Biologic Products to Report First Quarter 2015 Financial Results Apr 28 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK